TheNewswire
02 Sept 2026, 21:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
NeuroThera has initiated a Phase IIb clinical program for SCI-110 across three international academic centers. — Advancing to Phase IIb represents a critical milestone in the drug development pipeline, significantly reducing the risk of early-stage failure.
+0.60NeuroThera is pursuing FDA Orphan Drug Designation for SCI-110 to treat adult Tourette Syndrome. — Orphan status provides significant commercial advantages, including market exclusivity and potential tax credits, if granted.
+0.50Phase IIa results for SCI-110 showed an average tic reduction of 21% as measured by the Yale Global Tic Severity Scale. — Positive early efficacy data provides the fundamental clinical justification for further investment and development.
+0.40Continue reading
6 related stories
Search tags
NeuroThera has engaged RK Strategies, a U.S. government affairs and lobbying firm, to influence federal stakeholders and policy. — While supportive of market access, lobbying is a strategic administrative move rather than a clinical or financial catalyst.
+0.20Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
4h ago
